



Understanding Cannabinoid Receptor Signaling Complexity: Keys for Improved Therapeutic Drug Development

Guest Editor:

Prof. Dr. Paul L. Prather

Department of Pharmacology
and Toxicology, College of
Medicine, University of Arkansas
for Medical Sciences, 4301 W
Markham St, Little Rock, AR
72205, USA

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editor

Dear Colleagues,

Cannabinoid receptors (CBRs) activation results in both therapeutic, and unfortunately adverse, effects, which currently limits the clinical use of drugs in this class. However, mechanisms controlling cannabinoid receptor activation and subsequent intracellular signaling processes are highly complex and thus might be exploited to overcome these limitations to preferentially activate pathways responsible for therapeutic rather than adverse effects. Articles for this Special Issue are sought to provide improved knowledge to help harness these and other mechanisms of producing CBR signaling diversity and to lead to the development of cannabinoid-based drugs with enhanced therapeutic activity and reduced toxicity. Topics of interest include but are not limited to:

1. Orthosteric and allosteric CBR signaling;
2. CBR functional selectivity and bias signaling;
3. CBR-interacting proteins;
4. Signaling of non-canonical CBRs;
5. CBR-signaling networks;
6. Tissue-specific CBR signaling;
7. CBR signaling in cancer cells;
8. Molecular modeling of CBR ligands;
9. CBR structure and function.

